|[March 05, 2014]
Research and Markets: Global Biosimilars Market 2014-2018: Patent Expirations and More
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/j56s9s/global)
has announced the addition of the "Global
Biosimilars Market 2014-2018" report to their offering.
The analysts forecast the Global Biosimilars Market to grow at a CAGR of
27.58 percent over the period 2013-2018. One of the key factors
contributing to this market growth is the increasing number of patent
expirations. The Global Biosimilars Market has also been witnessing the
outsourcing of biosimilar manufacturing. However, the risks related to
drug failure could pose a challenge to the growth of this market.
Key vendors dominating this space include Biocon Ltd., Hospira Inc.,
Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas
Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La
Roche Ltd., 3SBio Inc., and Celltrion Inc.
Other vendors mentioned n the report are Actavis plc, Amgen Inc.,
AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton
S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc.,
Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare
Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR
Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck &
Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung (News - Alert) Biologics Co.
Ltd., Sanofi S.A., and Wockhardt Ltd.
Commenting on the report, an analyst from the team said: The manufacture
of biosimilar products requires specialized capabilities, meticulous
planning, highly skilled staff, and significant financial investment in
equipment, technology, materials, and personnel. Therefore, the
complexities and costs involved in the biosimilar development rises
along with the dip in their profit margins, hampering the overall
success of manufacturing biosimilar products. Thus, many vendors are
increasingly turning to CMOs and CROs that have already gained
proficiency in the field of manufacturing biosimilar products. The
wealth of knowledge, experience, understanding, technology, skills and
financial control that CMOs and CROs can provide to manufacturers, make
this a solution that many vendors are using at present. These
organizations employ well-trained professionals to develop and validate
analytical methods, providing pharmaceutical companies with a feasible
way of remaining competitive and financially viable. This new trend is
expected to have a positive impact on the growth of the market over the
next few years.
For more information visit http://www.researchandmarkets.com/research/j56s9s/global
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Unified Communications 's Homepage ]